There is ample evidence of the beneficial effects of SASP inhibitors in preclinical studies, such as those observed for the IL-1β receptor inhibitor anakinra, used in rheumatoid arthritis, or metformin, a treatment for type 2 diabetes which inhibits the transcription factor NF-κB [31]. The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.